Sep 4, 2025, 15:56
Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma
Servier shared a post on X:
“We’re thrilled to announce a licensing agreement for a promising treatment for Uveal Melanoma, a rare and aggressive eye cancer, developed by IDEAYA Biosciences.
Uveal melanoma is a rare and aggressive form of eye cancer that originates in the uveal tract, which includes the iris, ciliary body, and choroid.
At Servier, oncology is a top innovation priority — close to 70% of our R&D budget is dedicated to advancing treatments for rare cancers.
Read more in our press release.”
More Posts Featuring Servier.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 16:17
Sep 4, 2025, 16:08
Sep 4, 2025, 15:59
Sep 4, 2025, 15:51
Sep 4, 2025, 15:49
Sep 4, 2025, 15:48
Sep 4, 2025, 15:36
Sep 4, 2025, 15:34